anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is intended to provide a hair care preparation. The invention is directed to a hair care preparation (a hair regrowth agent, a hair growth agent or an agent for preventing hair loss) comprising as an effective component, an enzymatic or hydrolytic degradation product of a nucleoprotein and/or DNA or RNA, a deoxyoligonucleotide, a deoxymononucleotide, an oligopeptide, an oligonucleotide or a mononucleotide separated from the degradation product, or a mixture of at least two members selected from the degradation products or compounds. The effective component such as a deoxyoligonucleotide has a relatively small molecular weight, therefore, it is easy to be percutaneously absorbed. Further, it has a cell activation effect and a blood circulation-promoting effect when it is percutaneously absorbed. Therefore, when it is applied to the scalp, an excellent hair regrowth-promoting effect, hair growth effect and effect of preventing hair loss are exhibited. The hair care preparation of the invention is useful as a hair care pharmaceutical product, quasi drug or cosmetic product for mammals, particularly for humans, or a preparation to be added thereto.
Tiotropium Bromide is a long-acting bronchodilator that is used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma bronchodilator or bronchiolitis, which are substances that expand the bronchi and reduce resistance in the respiratory tract and increase airflow to the lungs. For Tiotropium Bromide found in inhaler capsules to treat COPD, determining the relevant impurities G and H, which are not UV active, is crucial. For this purpose, a new and sensitive liquid chromatography triple-quadrupole mass spectrometry (LC-MS/MS) detection with electrospray ionization by using multiple reaction monitoring in the positive mode method was developed and validated. The identity of the compounds was supported by using LC-Q/TOF. All chromatographic studies were performed with a Zorbax Eclipse XDB-C8 (150 mm x 4.6 mm, 5.0 µm) column with a total injection time of 13 min at a flow rate of 0.4 ml/min as a gradient. The limit of detection (LOD) and limit of quantitation (LOQ) in the current study range were determined as 1.0 ppb and 2.5 ppb, respectively. The results of the validation parameters following the ICH Q2(R1) guideline were determined within the acceptance criteria.
Volar locking plate fixation has been used as the gold standard treatment for intra-articular distal radius fractures. The need for postoperative immobilization after this type of fixation is controversial, with some authors advocating its use for analgesia. Conversely, the use of immobilization might retard the recovery of wrist range of motion and function. The objective of this study is to compare the level of pain and function of patients undergoing surgical fixation of distal radius fractures using or not postoperative immobilization. Patients will be randomly assigned to receive a plaster splint or conventional dressing immediately after the surgery. The main outcome is the level of pain in the first two weeks postoperatively.
Circadian rhythms play a crucial role in regulating various physiological processes, including specific immune functions that enhance the body's ability to anticipate and respond to threats effectively. However, research on the impact of circadian rhythms on osteoimmunology remains limited. Our study uncovered that circadian disruption leads to bone mass loss by reducing the population of Treg cells in the bone marrow. Furthermore, we observed a significant decrease in serum IL-10 cytokine levels in jet lagged mice. In our current investigation, we explored the anti-osteoclastogenic effects of IL-10 and found that IL-10 inhibits RANKL-induced osteoclastogenesis in a dose-dependent manner. Our findings suggest that the diminished anti-osteoclastogenic properties of Tregs under circadian disruption are mediated by IL-10 cytokine production. Moreover, our discoveries propose that administration of IL-10 or butyrate could potentially reverse bone mass loss in individuals experiencing jet lag.
The invention relates to a lotus seed damp-clearing leucorrhoea-arresting mixture. The lotus seed damp-clearing leucorrhoea-arresting mixture is prepared from carefully chosen Chinese herbal medicines according to a reasonable formula. Gynecological diseases are important problems as woman life trouble and can produce great influence on woman health. Abnormal leucorrhoea is a common problem, has etiology and pathogenesis of viscera function disorder and endogenous dampness or direct damp toxin and trichomonad infection of external genitalia, Ren belt damage due to damp, Ren channel insufficiency, poor belt and channel control, turbid vaginal discharge downward flowing to Bao and overflow at Yin orifice. The gynecological diseases have symptoms of white or light yellow leucorrhea, thick leucorrhea, no odor, continuous leucorrhea secretion, pale complexion, cold four limbs, mental fatigue, less intake and loose stool, pale tongue, white and greasy coated tongue and slow pulse. The lotus seed damp-clearing leucorrhoea-arresting mixture has effects of clearing damp and checking vaginal discharge, benefiting spleen and harmonizing stomach, tonifying liver and kidney, and activating blood to promote menstruation and is suitable for unusual leucorrhoea diseases such as reproductive system inflammation, bacterial infection, vaginal trichomoniasis infection, monilial infection, deficiency of spleen and kidney, dampness-heat and dampness-toxin.
CGA is defined as a "multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up" (1). The CST hub in Limerick provides a rapid, single point of access to an outpatient specialist geriatrician and allied health professional assessment. The bulk of this therapy is delivered in each of the hubs. This is considered 'usual' or routine care for the purposes of this trial.

The intervention will consist of domiciliary multidisciplinary CGA and intervention including nursing, medical and allied health assessment and intervention for frail older adults over age 75 who are discharged from the ED, or referred urgently from their General Practitioner and referred to the CST in Limerick. The bulk of this intervention will be delivered in the patient's own home. Each participant will be required to attend the hub for their medical review where they will access specialist geriatric medical expertise. A domiciliary visit to the older person within 24-48 hours of referral from the ED or within 24-48 hours of triage of GP referral by a member of the multidisciplinary team will be carried out. This person will act as the case coordinator for the duration of the intervention. During this visit, there will be a detailed assessment of the older adult. The assessment will include but not be limited to a falls assessment, assessment of mobility and stairs, transfer, personal care, activities of daily living (ADLs), social supports, cognition, lying \& standing blood pressures and nutritional assessment. Referrals will be made for domiciliary care to the appropriate healthcare professionals (nursing, OT, physiotherapy, dietetics etc) based on the findings of this holistic assessment. Interventions prescribed will be individualised based on patient needs. The investigators will use the template proposed by Ellis et al. (2017) to characterise the components of the CGA intervention.

The trial will assess the benefits of this domiciliary model of care on outcomes including the following: function, quality of life, patient satisfaction, primary and secondary healthcare use, nursing home admission, mortality and cost-effectiveness. Baseline measurement will be taken at their index visit with follow-up at six weeks and 6 months.
The purpose of this study is to examine and relate physiological, behavioral, and self-perceived changes after a period of hearing aid use and as a function of auditory training. The primary objective of this study is to determine how physiological changes may be related to functional changes. The design of this experiment also will allow for evaluation of training effects, in particular, whether training enhances physiological change and further whether specific training transfers functionally and physiologically to similar stimuli. The proposed project will focus on the following questions: 1) Is an experience-related behavioral change in hearing aid performance over time reflected as a neurophysiologic change in the central auditory system? 2) Does a neurophysiologic change occur prior to or in conjunction with an experience-related behavioral change in hearing aid performance over time? 3) Does behavioral training over an extended period of time modify the neurophysiologic representation of speech following the provision of hearing aids? 4) What is the relationship between physiologic, behavioral, and self-perceived change over time and is this relationship impacted by behavioral training? 5) Are neurophysiologic changes in acoustic representations at a pre-attentive level limited to trained stimuli or does auditory training following the provision of hearing aids alter neurophysiological responses to novel speech sounds with acoustic content similar to the trained stimuli? Forty-eight hearing-impaired adults between the ages of 18 and 60 with no hearing aid experience will serve as subjects. Subjects will be randomly assigned to one of two experimental groups: a. individuals who receive auditory exposure in the real-world only; b. individuals who receive intense, controlled auditory practice with feedback, in addition to auditory exposure in the real world. Dependent variables will include measures of behavioral function (frequency specific speech recognition and confidence in different levels of noise), physiological function (amplitude and latency of mismatch negativity), and self-perception (Abbreviated Profile of Hearing Aid Benefit) over time. Data will be analyzed to evaluate relative change over time for each dependent variable and also to examine the relationship between the dependent variables considering hours of hearing aid use and audibility as potential covariates.
Determine D816V c-Kit mutation status prior to initiating treatment. Information on FDA-approved test for the detection of D816V c-Kit mutation is available at http://www.fda.gov/companiondiagnostics.  
The recommended dose of imatinib mesylate is 400 mg/day for adult patients with ASM without the D816V c-Kit mutation. If c-Kit mutational status is not known or unavailable, treatment with imatinib mesylate 400mg/day may be considered for patients with ASM not responding satisfactorily to other therapies. For patients with ASM associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFRα, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.
Breast cancer is rarely curable after metastasis, and the therapeutic options for metastatic triple negative breast cancer (TNBC) are limited. The host immune response is strongly predictive for the effect of chemotherapy in patients with TNBC. In the present trial, we combine Atezolizumab, an inhibitory antibody against Programmed Death Ligand-1 (PD-L1), with chemotherapy. Thereby, we aim to release the brake on the chemo-induced immune response. The chemotherapeutic regime is a combination of anthracycline and cyclophosphamide, applied in a semi-metronomic fashion (pegylated liposomal doxorubicin every 2nd week and daily cyclophosphamide for 2/4 weeks). The investigators hypothesize that the semi-metronomic regime will induce immunological cell death and counter T regulatory cells, while maintaining the leukocyte counts and the ability of the effector immune cells to respond. The use of pegylated liposomal doxorubicin (Caelyx) minimizes the adverse effects of anthracyclines on the heart and allows for continued treatment beyond the otherwise mandatory anthracycline limits.
A capsule (10) of, for instance, hard gelatin for holding a substance such as medicine, food supplements or similar materials includes a capsule body (44) having a closed and an opposed open end with a predetermined length defined between the ends. A diaphragm (50) having a closed end and an opposed open end and a predetermined length there between seals off the body (44) and provides a first compartment (48) to hold a first medicine, food supplement, etc. A cap (60) is applied to the body (44) as is conventional in capsules. The space between the inner portion of the cap (60) and the diaphragm (50) defines a second compartment (64) for holding a second medicine, food supplement, etc. The contents of each compartment (48,64) may be wet or dry (e.g., powder or liquid.) This two-compartment capsule has particular relationships between the length along an axis of the capsule of the diaphragm (50) to that of the body (44), and particular dimensional parameters relating to the sidewall contact seal between the outer portion of the diaphragm (50) and the inner wall of the body (44), to provide adequate capsule sealing and stability during and after manufacture.
The invention relates to a natural plant maple leaf concentrated paste as well as a preparation method and an application thereof. The concentrated paste is prepared from the following raw materials: 83-88% of maple leaves, 4-6% of tea tree branches and leaves, 4-6% of camphor branches and leaves and 4-6% of persimmon tree branches and leaves. The preparation method comprises steps of processing the raw materials, soaking the raw materials, conducting internal mixing and conducting mixing. The invention also discloses the application of the concentrated paste. The natural plant maple leaf concentrated paste provided by the invention achieves the full utilization of pure natural plant resources, and the natural plant maple leaf concentrated paste is rich in raw material source, simple in preparation process and low in cos. The finished concentrated paste, which is prepared on the basis of the bio-transformation principle of a physical method, is green, safe ad environment-friendly, and the concentrated paste, as a food dye, can be used for preparing colored cooked glutinous rice or can be used for preparing base materials of hairdressing and colored painting skin care cosmetics, so as to lay a foundation for the development of the conventional colored cooked glutinous rice and the hairdressing skin care cosmetics.
INTRODUCTION: Low QRS peak-to-nadir voltage (LQRSV) is associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) and other cardiomyopathies. Recent studies have proposed criteria for LQRSV when screening athletes for cardiovascular disease. These criteria have not yet been evaluated in a large population of healthy young athletes.
METHODS: The target population was 10,728 (42.5% female, 57.5% male, mean age 18.1 ± 4.3 years) athletes who participated in mass ECG screenings between 2014 and 2021 at multiple sites across the United States including grade schools (11%), high schools (32%), colleges (50%), and professional athletic teams (6%) with digitally recorded ECGs and a standardized protocol. Since by design, complete follow up for outcomes and the results of testing were not available. Including only ECGs from initial evaluation among athletes 14-35 years of age and excluding those with right bundle branch block, left bundle branch block, Wolf-Parkinson-White pattern, reversed leads and 3 clinically diagnosed cardiomyopathies at Stanford, 8,679 (58% males, 42% females) remained eligible for analysis. QRS voltage was analyzed for each ECG lead and LQRSV criteria were applied and stratified by sex.
RESULTS: QRS voltage was lower in all leads in female athletes compared to male athletes. Using traditional limb lead criteria or precordial lead criteria, the prevalence of LQRSV was significantly lower in males than females (P < .001). Strikingly, LQRSV using the Sokolow-Lyon Index was present in 1.9% of males and 9.8% of females (P < .001). Applying first percentile for LQRS amplitude criteria provided possible values for screening young athletes for LQRSV.
CONCLUSIONS: LQRSV is more common among female athletes than male athletes using established criteria. Using first percentile sex-specific cut points should be considered in future analyses. Proposed novel LQRSV criteria in young athletes should be specific for males and females.
An 84-year-old woman underwent laparoscopic partial hepatectomy for a single 3.0-cm-diameter nodule of hepatocellular carcinoma at segment 5. Although the postoperative condition was uneventful, multiple recurrences were observed six months after hepatic resection. Transcatheter arterial chemoembolization (TACE) was the second-line therapy. However, she was later diagnosed as TACE refractory due to residual tumor and presence of portal vein tumor thrombus. Third-line therapy was the combination of atezolizumab and bevacizumab, which was discontinued after 22 courses due to disease progression. Two months after the conclusion of chemotherapy, sudden onset of purpura was observed around her eyes and on her lower legs. Laboratory tests revealed severe thrombocytopenia, and she was diagnosed with secondary immune thrombocytopenic purpura. Steroids and immunoglobulin therapy were then administered. Although the immature platelet fraction increased after treatment, the platelet count did not. The patient died of intracranial hemorrhage 10 days after initiation of steroid and immunoglobulin therapy.
In one aspect, the invention provides a method for making a hydrophilic-silk composition. The method includes providing at least one strand of silk fiber, treating the silk fiber with an alkaline solution to provide at least one strand of degummed silk fiber, and treating the degummed silk fiber with a treatment solution to provide a hydrophilic-silk composition. The degummed silk fiber or the hydrophilic-silk composition is further immobilized with at least one reagent to make a silk-based diagnostic composition. The invention provides a silk-based diagnostic composition made by the method of the invention, and a diagnostic device that comprises the silk-based diagnostic composition. In another aspect, the invention provides a method of making a diagnostic device. The method includes providing at least one strand of a diagnostic-fiber composition, providing at least one strand of a hydrophobic-fiber composition, inter-weaving the at least one strand of the diagnostic-fiber composition and the at least one strand of the hydrophobic-fiber composition. In one embodiment, the diagnostic-fiber composition and the hydrophobic-fiber composition are both based on silk.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic capable of exhibiting excellent crease improving effect and good feeling to users by combining a guanidine derivative having a specific structure or its acid addition salt with a synthetic sphingosine. SOLUTION: This skin cosmetic is obtained by combinedly using (A) a guanidine derivative of formula I [A and B are each a 2-8C alkylene; D is a direct bond, CO or a 1-6C alkylene; E is H, an alkyl, an aralkyl or an aryl; (m) is 1-6; (n) is 0-6; R<1> is H, an alkyl, (AO)m -(BO)n -D-E] of formula II [(k) is 1-10; G is H, OH, COOH, sulfonic acid or phoshoric acid] or its acid addition salt and (B) a synthetic sphingosine derivative of formula III (R<2> is a 4-40C hydrocarbon; R<3> to R<7> are each H or a 1-10C hydrocarbon; X and Y are each H or an alkyl). The skin cosmetic is preferably obtained by blending 0.001-50wt.% component A with 0.0001-10wt.% component B. An organic acid or its ester in an amount of 0.001-30wt.% may further be added to the system. The component of formula I is e.g. obtained from a compound of formula IV.
This is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted in Germany at 3-6 sites. Subjects will be randomised to one of two treatment sequences (A and B). Each treatment period will last 7 days with a wash-out period of 7 days between treatments. Half of the subjects will start with treatment A followed by treatment B while the other half will start with treatment B followed by treatment A. A safety follow-up visit will be performed 3 days after last dose of the tested medication.

The main assessment is an urticaria activity score. After a Pulse-controlled ergometry (PCE) provocation test subjects will be rated on their number of wheals and their itch severity, resulting in a sum score ranging from 0 to 6 points.
Replication repair deficiency (RRD) is a pan-cancer mechanism characterized by abnormalities in the DNA mismatch repair (MMR) system due to pathogenic variants in the PMS2, MSH6, MSH2, or MLH1 genes, and/or in the polymerase-proofreading genes POLE and POLD1. RRD predisposition syndromes (constitutional MMR deficiency, Lynch, and polymerase proofreading-associated polyposis) share overlapping phenotypic and biological characteristics. Moreover, cancers stemming from germline defects of one mechanism can acquire somatic defects in another, leading to complete RRD. Here we describe the recent advances in the diagnostics, surveillance, and clinical management for children with RRD syndromes. For patients with constitutional MMR deficiency, new data combining clinical insights and cancer genomics have revealed genotype-phenotype associations and helped in the development of novel functional assays, diagnostic guidelines, and surveillance recommendations. Recognition of non-gastrointestinal/genitourinary malignancies, particularly aggressive brain tumors, in select children with Lynch and polymerase proofreading-associated polyposis syndromes harboring an RRD biology have led to new management considerations. Additionally, universal hypermutation and microsatellite instability have allowed immunotherapy to be a paradigm shift in the treatment of RRD cancers independent of their germline etiology. These advances have also stimulated a need for expert recommendations about genetic counseling for these patients and their families. Future collaborative work will focus on newer technologies such as quantitative measurement of circulating tumor DNA and functional genomics to tailor surveillance and clinical care, improving immune surveillance; develop prevention strategies; and deliver these novel discoveries to resource-limited settings to maximize benefits for patients globally.
The invention discloses a nano degrading agent for degrading cytoplasmic protein in a broad spectrum and preparation and application thereof. The nanometer degradation agent is a nanometer particle which is composed of an antibody as an inner core and a metal ion sediment as an outer shell and can be prepared by a biomineralization method. The metal ions include divalent and trivalent cations of most transition metal elements as well as other metal elements, such as: ca  2+  、Co  2+  、Zn  2+  、Cr  3+  And reacting with anions such as hydrogen phosphate, phosphate radical and carbonate on the surface of the antibody to form micro-precipitates, thereby obtaining the mineralized nanoparticles. The antibodies all contain an Fc fragment. The nanoparticle can be degraded in a certain acidic environment, the released antibody can identify target protein in cells, and meanwhile, the antibody binds E3 ubiquitin ligase in cells, and the target protein is degraded through a ubiquitin-proteasome pathway. The nanometer degradation agent can be used for treating diseases related to abnormal proteins such as anti-tumor diseases and nervous system diseases and carrying out various function researches on knocking down proteins at a cellular level.